Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« Many Faces of a Face - Neuroesthetics | Main | European Neurosociety Developments »

January 28, 2008

NIO bets big in capital

Email This Entry

Posted by Zack Lynch

Zack%20Lynch%20Neurotech%20SF%20Business%20Times.jpgRon Leuty at The San Francisco Business Times interviewed me last week and the result was the following pithy article: Neuroscience organization bets big in capital: Industry group seeks $200M to research brain abnormalities

A young, San Francisco-based trade organization representing neuroscience companies has lined up companies nationally and heavy hitters in the nation's capital to lobby for a $200 million superfund to help bring products to market for brain and nervous system diseases ranging from Alzheimer's to insomnia.

The 17-month-old Neurotechnology Industry Organization is working with Kirkpatrick & Lockhart Preston Gates Ellis LLP -- the New York law firm also known as K&L Gates, as in William Gates Sr., the father of Microsoft Corp. co-founder Bill Gates -- to push its plan in Washington, D.C.

The NIO's five-part plan, dubbed a "Human Genome Project for the brain" by Executive Director Zack Lynch, would earmark:

* $80 million for the National Institutes of Health's "Blueprint for Neuroscience Research," developed by 16 institutes that offer grants for neuroscience issues ranging from depression and Parkinson's Disease to spinal cord research and traumatic brain injury;
* $75 million to the NIH's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs for neuroscience startups and research;
* $30 million to increase staffing and training at the U.S. Food and Drug Administration to reduce a regulatory bottleneck that has delayed approval of some therapies;
* $10 million a year for studying the societal implications -- including ethical and legal questions -- of advancing neurotechnologies; and
* $5 million annually for a national neurotechnology coordination office to aggregate what federal agencies as diverse as the NIH and the Department of Defense are doing in neurotech.

The plan would accelerate bringing neuroscience innovations to patient bedsides, Lynch said. Parts of the program, like SBIR and STTR, also would help create new companies in neurotech centers like the Bay Area, Lynch said.

Comments (0) + TrackBacks (0) | Category: NIO


POST A COMMENT

Thanks for signing in, . Now you can comment. (sign out)

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)





Remember me?


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Neurotech 2010: Translational Researchers Highlight Innovation
The Neuro Revolution in China Progressing
Speakers for Neurotech 2010 - Boston, May 19-20
Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow
McGovern Institue for Brain Research at MIT Goes Web 2.0
The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics
Neuropharma FDA Approvals Down in 2009
Tel Aviv Neurotech Cluster Thrives